News & Updates

Product Highlight - LANTUS

16 Jun 2021

Insulin Glargine 100 units/mL vial

Product Highlight - LANTUS

16 Jun 2021

Product Highlight - SOLIQUA

16 Jun 2021

Insulin glargine + Lixisenatide 100 u/mL + 50 mcg/mL solution for injection (3 mL pre-filled pen); 100 u/mL + 33 mcg/mL solution for injection (3 mL pre-filled pen)

Product Highlight - SOLIQUA

16 Jun 2021

Product Highlight - TOUJEO

16 Jun 2021

Insulin Glargine 300 units/mL pre-filled pen

Product Highlight - TOUJEO

16 Jun 2021

Liposomal bupivacaine no better than HCl formulation in total joint arthroplasty

15 Jun 2021

Treatment with liposome bupivacaine does not provide a significant benefit to patients with total joint arthroplasty relative to bupivacaine HCl formulation, reports a study.

Liposomal bupivacaine no better than HCl formulation in total joint arthroplasty

15 Jun 2021

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

15 Jun 2021

New drug applications approved by US FDA as of 01-15 June 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

15 Jun 2021

Iberdomide confers dermatologic benefit for SLE

15 Jun 2021 by

A high dose of the high-affinity cereblon ligand iberdomide delivered beneficial effects on the cutaneous manifestations of systemic lupus erythematosus (SLE), according to a phase II study presented at EULAR 2021.

Iberdomide confers dermatologic benefit for SLE

15 Jun 2021

Ceftazidime-avibactam brightens outlook in CRE bacteraemia

15 Jun 2021

Treatment with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae (CRE) bacteraemia appears to reduce the risk of death over 2 weeks when compared with colistin, according to a study.

Ceftazidime-avibactam brightens outlook in CRE bacteraemia

15 Jun 2021

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

15 Jun 2021

The fixed-dosing omadacycline strategy demonstrates consistent safety and efficacy in patients with community-acquired bacterial pneumonia (CABP), regardless of body mass index (BMI), according to a phase III trial.

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

15 Jun 2021

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021 by

Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021

High-dose thiamine as IV push safe to administer

14 Jun 2021

Administering thiamine ≤200 mg as an intravenous (IV) push is safe, with no serious adverse events (AEs) seen, reveals a study.

High-dose thiamine as IV push safe to administer

14 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Product Highlight - LANTUS

Product Highlight - LANTUS

Product Highlight - SOLIQUA

Product Highlight - SOLIQUA

Product Highlight - TOUJEO

Product Highlight - TOUJEO

Liposomal bupivacaine no better than HCl formulation in total joint arthroplasty

Liposomal bupivacaine no better than HCl formulation in total joint arthroplasty

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

Iberdomide confers dermatologic benefit for SLE

Iberdomide confers dermatologic benefit for SLE

Ceftazidime-avibactam brightens outlook in CRE bacteraemia

Ceftazidime-avibactam brightens outlook in CRE bacteraemia

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

PAP-treated sleep apnoea tied to reduced COVID-19 risk

PAP-treated sleep apnoea tied to reduced COVID-19 risk

High-dose thiamine as IV push safe to administer

High-dose thiamine as IV push safe to administer